
    
      There will be 7 cohorts enrolled, each consisting of 8 subjects.

      Cohorts 1 - 4 will be orally administered up to 2000mg single doses of DS102 on Day 1.

      Cohorts 5 - 7 will be orally administered up to 2000mg multiple daily doses of DS102 for 28
      days.

      The primary objective is to assess the safety and plasma pharmacokinetics of single and
      multiple daily oral doses of DS102.
    
  